Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Bayer announced the premature termination of a significant late-stage trial for an experimental anti-clotting drug. The trial was halted due to the drug's inferior performance when compared to Bristol-Myers Squibb and Pfizer's well-established Eliquis in preventing strokes among high-risk patients.
The development dealt a major blow to the embattled German pharmaceutical giant and raised concerns about the fate of its most promising medium-term project, observed Reuters.
Setback for Bayer Amidst Ongoing Challenges
The trial's halt, following the recommendation of independent trial supervisors, represents yet another setback for Bayer. Yahoo noted that the company has been grappling with a weak herbicide business, mounting debt, and the burden of U.S. lawsuits related to the alleged carcinogenic effects of its widely-used Roundup weedkiller.
Taking the helm as the new CEO, Bill Anderson intends to explore options to revitalize Bayer's battered share price. Efforts include potentially dividing the company into separate entities and streamlining management decision-making through the reduction of management positions.
Bayer will conduct a comprehensive analysis of the trial's data following its discontinuation. Known as OCEANIC-AF, the trial was initiated in August 2022.
The company stated that the trial's safety data remained consistent with prior studies. While this trial was halted, the independent supervisors recommended continuing a separate phase III trial named OCEANIC-STROKE.
This trial aims to evaluate the efficacy of asundexian in preventing recurring strokes among participants who have already experienced one.
Bayer’s Ambitious Goals and Implications
Bayer had set an ambitious goal for asundexian, aiming to generate over 5 billion euros in peak annual sales. This objective sought to compensate for declining revenue from one of Bayer's pharmaceutical best-sellers, the blood thinner Xarelto.
The patent protection for Xarelto in key European markets is set to expire in 2026. Consequently, the trial's termination also poses a setback for Stefan Oelrich, the head of Bayer's pharmaceutical unit. Oelrich had relied on asundexian's success to drive significant expansion in the United States market, the largest pharmaceutical market globally.
In contrast to its partnership on the Xarelto franchise, where Bayer shared development costs with Johnson & Johnson and ceded most of the U.S. market, Bayer embarked on the asundexian studies independently. The company had prepared to make substantial investments in U.S. marketing and distribution.
Bayer's stock price has fluctuated due to the challenges it faces, and concerns among shareholders have escalated.
Photo: Bayer Newsroom
